NCT00575848 Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia Status TERMINATED Phase PHASE1
NCT00575666 Intranasal Insulin Treatment in Patients With Schizophrenia Status COMPLETED Phase PHASE4
NCT00573417 A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia Status COMPLETED Phase PHASE4
NCT00573300 Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study Status COMPLETED Phase N/A
NCT00573287 First Episode Schizophrenia and Cannabis-Related Disorder Study Status COMPLETED Phase NA
NCT00570063 Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo Status TERMINATED Phase PHASE2
NCT00569504 Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics Status UNKNOWN Phase N/A
NCT00567710 A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study Status COMPLETED Phase PHASE2
NCT00567281 Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Original Study Status COMPLETED Phase NA
NCT00567203 A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia Status COMPLETED Phase PHASE1
NCT00567099 Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole Status UNKNOWN Phase NA
NCT00567034 Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects Status COMPLETED Phase PHASE1
NCT00566631 An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia Status COMPLETED Phase PHASE3
NCT00565175 Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia Status COMPLETED Phase PHASE4
NCT00564096 Transcranial Magnetic Stimulation (TMS) in Schizophrenia Status UNKNOWN Phase PHASE2/PHASE3
NCT00563706 Study Evaluating Vabicaserin in Subjects With Schizophrenia Status COMPLETED Phase PHASE2
NCT00563017 Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone Status UNKNOWN Phase NA
NCT00562926 Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong Chinese Status COMPLETED Phase N/A